Pyrazole-Infused Metal Complexes: Anticancer Activity, DNA Cleavage, and Biophysical Insights into DNA/BSA Interactions by Tankadhar Behera (22267115)

Subjects:

Changes in growth characteristics (A = shoot fresh weight; B = shoot dry weight; C = root fresh weight; D = root dry weight) of M. stenopetala under drought conditions.... by Nadia Khater (22553166)

Subjects:

PVS_ratio changes, ΔPVS_ratio, for different radiation doses within each treatment period: 0M–3M(a), 3M–12M(b), and 12M–FollowUp(c). by Ruitian Song (11045127)

Subjects:

PVS_volume changes, ΔPVS_volumes, for various radiation doses within each treatment period: 0M–3M(a), 3M–12M(b), and 12M–FollowUp(c). by Ruitian Song (11045127)

Subjects:

Summary of miRNAs sequencing data quality. by Zhaowen Tan (12283502)

Subjects:

The miRNA target genes. by Zhaowen Tan (12283502)

Subjects:

Differential miRNA target gene pathway enrichment bubble map. by Zhaowen Tan (12283502)

Subjects:

The global disease burden of <i><i>Klebsiella pneumoniae</i></i> associated LRI for both sexes in 204 countries and territories. (a) The number of DALYs in 2021; (b) The EAPC of DA... by Juanjuan Li (399633)

Subjects:

Seasonal spatial-temporal trend of NDVI in burned areas across Africa (2001–2020). Percentages (%) of increases or decreases (%) based on the Mann-Kendall test and statistically significant (<i>p</i> < 0.05) and non-significant (p > 0.05) values. by Oswaldo Maillard (20660661)

Bar charts showing the numbers of significantly differentially expressed genes for the different contrasts. by Gillian P. McHugo (8965919)

“…<p>The extent of the bar above and below 0 on the vertical axis indicates the numbers of significantly differentially expressed genes (DEGs; B-H <i><i>P</i></i><sub>adj.…”

Statistically significant linear increase in use of antidementia medications and antipsychotics during the observed time period. by Jelena Filimonovic (22305307)

Subjects:

Crude and age-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Crude and type-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Crude and residence-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Fig 16 - by Zhezhe Zhang (19704587)

Subjects:

Fig 25 - by Zhezhe Zhang (19704587)

Subjects:

Fig 9 - by Zhezhe Zhang (19704587)

Subjects:

Fig 24 - by Zhezhe Zhang (19704587)

Subjects:

Fig 15 - by Zhezhe Zhang (19704587)

Subjects:

Fig 23 - by Zhezhe Zhang (19704587)

Subjects: